{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Cao Y"],"pubmed_abstract":["<h4>Background</h4>The combination of low-dose nivolumab with triple metronomic chemotherapy (TMC-I) proposes a novel approach, potentially enhancing patient prognosis while mitigating financial barriers. The purpose of this study was to compare the cost-effectiveness of TMC-I compared to triple metronomic chemotherapy (TMC) in advanced head and neck squamous cell carcinoma (HNSCC) patients in China, the largest developing country.<h4>Methods</h4>A partitioned survival model (PSM) was developed based on a randomized clinical trial. Costs and utility were derived from open-access databases and literatures. The primary outcome was incremental cost-effectiveness ratio (ICER). A willingness-to-pay (WTP) threshold of ¥44,679/QALY based on supply-side and ¥134,037/QALY based on demand-side were "],"journal":["Frontiers in oncology"],"pagination":["1542792"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12433840"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China."],"pmcid":["PMC12433840"],"pubmed_authors":["Fang Y","Cao Y","Shi F","Wei X","Han S"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China.","description":"<h4>Background</h4>The combination of low-dose nivolumab with triple metronomic chemotherapy (TMC-I) proposes a novel approach, potentially enhancing patient prognosis while mitigating financial barriers. The purpose of this study was to compare the cost-effectiveness of TMC-I compared to triple metronomic chemotherapy (TMC) in advanced head and neck squamous cell carcinoma (HNSCC) patients in China, the largest developing country.<h4>Methods</h4>A partitioned survival model (PSM) was developed based on a randomized clinical trial. Costs and utility were derived from open-access databases and literatures. The primary outcome was incremental cost-effectiveness ratio (ICER). A willingness-to-pay (WTP) threshold of ¥44,679/QALY based on supply-side and ¥134,037/QALY based on demand-side were ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-04-08T19:54:35.338Z","creation":"2026-04-08T14:36:18.936Z"},"accession":"S-EPMC12433840","cross_references":{"pubmed":["40958881"],"doi":["10.3389/fonc.2025.1542792"]}}